12:00 AM
Feb 09, 2009
 |  BC Week In Review  |  Company News  |  Other News

Rigel autoimmune news

Rigel postponed partnership plans for tamatinib fosidum ( R788) and cut preclinical research programs in virology and oncology to lower operating expenses and conserve cash. The company will reduce headcount by 36 (20%) to 145, with cuts coming from research and...

Read the full 190 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >